Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo (for alirocumab)
Drug: Alirocumab
Drug: Lipid-Modifying Therapy (LMT)

First Posted Date: 2014-04-08

Last Posted Date: 2016-10-04

Lead Sponsor: Sanofi

Target Recruit Count: 216

Registration Number: NCT02107898

Locations: 🇯🇵
Investigational Site Number 392016, Adachi-Ku, Japan
🇯🇵
Investigational Site Number 392012, Chuo-Ku, Japan
🇯🇵
Investigational Site Number 392024, Aki-Gun, Japan

and more 29 locations

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Capecitabine
Drug: Aflibercept AVE0005
Drug: Oxaliplatin SR96669

First Posted Date: 2014-03-12

Last Posted Date: 2014-11-18

Lead Sponsor: Sanofi

Registration Number: NCT02085005

Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Device: glucose meter
Device: BGStar

First Posted Date: 2014-03-07

Last Posted Date: 2017-05-03

Lead Sponsor: Sanofi

Target Recruit Count: 241

Registration Number: NCT02082028

Locations: 🇮🇹
Investigational Site Number 016, Andria (BA), Italy
🇮🇹
Investigational Site Number 011, Avezzano, Italy
🇮🇹
Investigational Site Number 006, Bergamo, Italy

and more 17 locations

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: CABAZITAXEL XRP6258
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2014-02-28

Last Posted Date: 2016-06-02

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT02074137

Locations: 🇮🇳
Investigational Site Number 356003, New Delhi, India
🇮🇳
Investigational Site Number 356005, Kollkata, India
🇮🇳
Investigational Site Number 356002, Trivandrum, India

Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Device: iBGStar
Device: Traditional Glucometer

First Posted Date: 2014-02-27

Last Posted Date: 2016-04-14

Lead Sponsor: Sanofi

Target Recruit Count: 186

Registration Number: NCT02073188

Locations: 🇮🇹
Sanofi -Aventis Administrative Office, Milano, Italy

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Phase 2

Active, not recruiting

Conditions: Usher's Syndrome

Interventions: Drug: Blood draw for the laboratory assessment

First Posted Date: 2014-02-17

Last Posted Date: 2024-12-03

Lead Sponsor: Sanofi

Target Recruit Count: 9

Registration Number: NCT02065011

Locations: 🇺🇸
Oregon Health and Science University Site Number : 840001, Portland, Oregon, United States
🇫🇷
Investigational Site Number : 250001, Paris, France

Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Cisplatin
Drug: DOCETAXEL XRP6976
Drug: Dexamethasone

First Posted Date: 2014-02-13

Last Posted Date: 2015-10-08

Lead Sponsor: Sanofi

Target Recruit Count: 35

Registration Number: NCT02061631

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: RA

Interventions: Drug: Sarilumab
Device: Auto-Injector Device (AID)
Device: Pre-filled Syringe (PFS)
Drug: Methotrexate
Drug: Sulfasalazine
Drug: Leflunomide
Drug: Hydroxychloroquine

First Posted Date: 2014-02-07

Last Posted Date: 2017-06-20

Lead Sponsor: Sanofi

Target Recruit Count: 217

Registration Number: NCT02057250

Locations: 🇨🇱
Investigational Site Number 152050, Santiago, Chile
🇨🇱
Investigational Site Number 152007, Viña Del Mar, Chile
🇲🇽
Investigational Site Number 484005, Monterrey, Mexico

and more 50 locations

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Insulin glargine/lixisenatide Fixed Ratio Combination
Drug: Insulin glargine (HOE901)
Drug: Lixisenatide (AVE0010)
Drug: Metformin

First Posted Date: 2014-02-07

Last Posted Date: 2017-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 1170

Registration Number: NCT02058147

Locations: 🇺🇸
Investigational Site Number 840023, Tempe, Arizona, United States
🇺🇸
Investigational Site Number 840067, Santa Ana, California, United States
🇺🇸
Investigational Site Number 840089, Atlanta, Georgia, United States

and more 270 locations

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
Drug: Insulin glargine (HOE901)
Drug: Metformin (Background Drug)

First Posted Date: 2014-02-07

Last Posted Date: 2017-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 736

Registration Number: NCT02058160

Locations: 🇺🇸
Investigational Site Number 840594, Atlanta, Georgia, United States
🇺🇸
Investigational Site Number 840588, Idaho Falls, Idaho, United States
🇺🇸
Investigational Site Number 840580, Arlington Heights, Illinois, United States

and more 233 locations

Home Terms & Conditions Privacy Policy